BIIB · earnings call history
Biogen Q1 FY26 — Growth portfolio +12% as pending Apellis deal reframes trajectory
Read the briefBiogen Q4 FY25 — Pipeline Transformation and Growth Product Momentum
Read the briefBiogen Q3 FY25 — Strong Launch Product Growth and Pipeline Advancement
Read the briefBiogen Q4 FY24 — New Product Growth Offsets MS Decline, Pipeline Progress
Read the briefBrowse all US companies on the earnings-call register.